Resarchers discover how CHPs vividly display collagen turnover during cancer development.

Custom Conjugates

Our In Vivo CHPs are conjugated with sCy 7.5 for near-IR detection. Contact us for customized conjugates.

Contact Us
Understanding Multiple Myeloma

Understanding Multiple Myeloma

Multiple Myeloma(MM) is a neoplastic plasma-cell disorder characterized by malignant plasma cells in the bone marrow. These plasma cells develop from genetic and microenvironmental changes. MM is the second most common hematologic malignancy worldwide, with about 100,000 incidences annually. As an active disease, patients develop several pathological conditions and organ damage such as hypercalcemia, lytic bone lesions, anemia, renal insufficiency, and hyper-viscosity.
Current Treatment Challenges
Treatment options have incorporated novel drugs in therapeutic backbones, however many factors such as drug resistance, age, and side effects from medicine make MM treatment complex. The current standard of care includes local and systemic therapies. Unfortunately, most MM patients are elderly and with comorbidities, which precludes aggressive therapies.
Why CHPs?
By leveraging our Collagen Hybridizing Peptides, 3Helix allows for a deeper understanding of the collagen turnover apparent during cancer development – essential in monitoring MM’s progression. Our innovations are paving the path to new perspectives on Multiple Myeloma, offering hope to the thousands affected.